Keywords: ImmunoGen, Roche, Trastuzumab emtansine, T-DM1, Breast cancer, Medivation, astellas, Xtandi, Prostate cancer, GlaxoSmithKline, Dabrafenib, Millennium, Seattle Genetics, Takeda, Adcetris
More highlights from ESMO Congress
Article | 02 October 2012
In further news coming out at the European Society of Medical Oncology (ESMO) Congress taking place in Vienna, Austria (see ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
